---
title: "Sanofi higher after Q3 beat driven by Regeneron-partnered Dupixent"
description: "Sanofi shares rose slightly after reporting Q3 2025 results that surpassed expectations, driven by strong sales of its asthma drug Dupixent, which generated €4.2B with a 26% YoY growth. Total sales re"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262611409.md"
published_at: "2025-10-24T11:30:10.000Z"
---

# Sanofi higher after Q3 beat driven by Regeneron-partnered Dupixent

> Sanofi shares rose slightly after reporting Q3 2025 results that surpassed expectations, driven by strong sales of its asthma drug Dupixent, which generated €4.2B with a 26% YoY growth. Total sales reached €12.4B, exceeding analyst projections. Despite an 8% decline in vaccine sales, Sanofi anticipates high single-digit sales growth and low double-digit EPS growth for 2025. The company is in discussions with U.S. policymakers regarding drug pricing and has expanded its insulin savings program to improve access.

Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, which is marketed in collaboration with Regeneron (NASDAQ:REGN). The Paris-based firm posted €12.4B ($14.4B) in sales and €2.91 ($3.38) of business earnin...

### Related Stocks

- [SNYNF.US - Sanofi](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 4-Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant | Sanofi has ousted CEO Paul Hudson after a six-year tenure marked by a stalled turnaround and pressure on vaccine sales.  | [Link](https://longbridge.com/en/news/275748711.md) |
| 17:31 ETAtopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors \| DelveInsight | The atopic dermatitis market is projected to grow significantly by 2034, driven by the introduction of new therapies and | [Link](https://longbridge.com/en/news/276080710.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |
| Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns | Upstream Bio Inc. (NASDAQ:UPB) shares fell over 54% following mixed results from its asthma drug trials, despite analyst | [Link](https://longbridge.com/en/news/275923255.md) |
| GSK's Exdensur Approved in EU as Add-on Treatment for Severe Asthma, Chronic Rhinosinusitis | GSK's Exdensur Approved in EU as Add-on Treatment for Severe Asthma, Chronic Rhinosinusitis | [Link](https://longbridge.com/en/news/276103226.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.